Prostate cancer is the third leading cause of death from cancer in men in Canada. However, prostate cancer is highly treatable if diagnosed early. Unfortunately, due to lack of cost-effective and meaning test detecting the early presence of the cancer. Most prostate cancer (92%) are found when the career is spreading to nearby organs.
Colorectal cancer (CRC) is the second most common cancer-related cause of death in Canada. This high mortality rate is largely due to the lack of a cost-effective, patient-accepted and sensitive screening tool. Metabolomic Technologies Inc. (MTI) has developed a nuclear magnetic resonance (NMR)-based urinary diagnostic test for detecting colonic polyps (PolypDx™).
The proposed project is for the intern to develop an algorithm to decide on the suitability of a group of chemical compounds to transfer from one detection instrument (low throughput) to another detection instrument (high throughput). For ease of use and cost considerations it is preferable for these chemical compounds to measured using a high throughput instrument. The company has validated a set of compounds on the low throughput instrument and would like to transfer these to a high throughput instrument.
Join a thriving innovation ecosystem. Subscribe now
